Zimmer Continuum Metal on polyethylene (MoP) PostMarket Clinical Monitorup (PMCF) -tutkimus
Tuleva markkinoille saattamisen jälkeinen kliininen seurantatutkimus Continuum Metalista polyeteeni-asetabulaarisessa järjestelmässä
This is a prospective, multi-center, non-randomized, non-controlled study designed to obtain survival and outcome data on the Continuum Metal on Polyethylene Acetabular System when used in primary total hip arthroplasty.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
The safety and performance of the Continuum Metal on Polyethylene Acetabular System will be confirmed by the assessment of survival and outcome data. Assessments will include standard scoring systems, radiographs and adverse event records. Data will be used to monitor pain, mobility, and survivorship of the Continuum Metal on Polyethylene Acetabular system in primary total hip arthroplasty. Metal ion (cobalt, chromium and titanium) and renal function (BUN, Creatinine and GFR) levels will be analyzed for a subset of the enrolled study subjects.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Todellinen)
Ilmoittautuminen
Yhteystiedot ja paikat
Opiskelupaikat
-
-
California
-
Fremont, California, Yhdysvallat, 94538
- Sah Orthopaedic Associates
-
-
Colorado
-
Denver, Colorado, Yhdysvallat, 80204
- Denver Health Medical Center
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Patients from surgeons medical practice who are candidates for primary hip arthroplasty.
The study population will be comprised of 300 males and females who require primary total hip arthroplasty. Subjects will be enrolled at up to 7 clinical sites. Subjects must be geographically accessible throughout the study and be willing and able to attend required follow-up appointments. Candidates who express interest in study participation will be offered informed consent, and eligibility will be determined based upon the inclusion/exclusion criteria.
Kuvaus
Inclusion Criteria
-
Patient is 18 to 75 years of age, inclusive.
-
Patient is skeletally mature.
-
Patient qualifies for primary unilateral or bilateral (simultaneous or staged) total hip arthroplasty (THA) based on physical exam and medical history including the following:
- Avascular necrosis (AVN)
- Osteoarthritis
- Inflammatory arthritis (i.e., Rheumatoid arthritis)
- Post-traumatic arthritis
-
Patient has no history of previous prosthetic replacement device of any type, including surface replacement arthroplasty, endoprosthesis, etc. of the affected hip joint(s).
-
Patient has moderate, marked or disabling pain.
-
Patient is willing and able to provide written informed consent.
-
Patient is willing and able to cooperate in the required post-operative therapy.
-
Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.
-
Patient has participated in the Informed Consent process and has signed the IRB approved informed consent.
Exclusion Criteria:
-
The patient is:
- A prisoner
- Mentally incompetent or unable to understand what participation in the study entails
- A known alcohol or drug abuser
- Anticipated to be non-compliant
-
The patient has a neuromuscular disorder, vascular disorder or other conditions that could contribute to prosthesis instability, prosthesis fixation failure or complications in postoperative care.
-
The patient has a neurologic condition in the ipsilateral or contralateral limb which affects lower limb function.
-
The patient has a diagnosed systemic disease that could affect his/her safety or the study outcome.
-
The patient is known to be pregnant.
-
The patient is unwilling or unable to give consent or to comply with the follow-up program.
-
The patient has received an investigational drug or device within the previous 6 months.
-
The patient has an active or latent infection in or about the affected hip joint or an infection distant from the hip joint that may spread to the hip hematogenously.
-
The patient has insufficient bone stock to fix the component. Insufficient bone stock exists in the presence of metabolic bone disease (i.e., osteoporosis), cancer, and radiation. Note: Dual Energy X-ray Absorptiometry (DEXA) may be used to assess the presence of adequate bone stock.
-
The patient has osteoradionecrosis in the affected hip joint.
-
The patient has a known sensitivity or allergic reaction to one or more of the implanted materials.
-
The patient has known local bone tumors and/or cysts in the operative hip.
-
The patient has a Body Mass Index (BMI) > 40.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: PROSPECTIVE
Ryhmien/kohorttien lukumäärä
Kohortit ja interventiot
Ryhmä/KohorttiRyhmä/Kohortti |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Continuum Acetabular System
Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System |
Used in primary hip arthroplasty
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Survivorship
Aikaikkuna: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Based on removal or intended removal of the device and determined using the Kaplan-Meier method. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Safety / Adverse Events
Aikaikkuna: Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Safety will be evaluated by monitoring the frequency and incidence of device related adverse events or unanticipated adverse device effects in investigational subjects. |
Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Pain and Function / HHS
Aikaikkuna: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Pain and function will be measured using the Harris Hip Score self assessment. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Pain and Function / OHS
Aikaikkuna: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Pain and function will be measured using the Oxford Hip Score self assessment. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Health Status / SF-12
Aikaikkuna: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Health status will be measured using the SF-12 self assessment. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Health Status / Radiographic Parameters
Aikaikkuna: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
X-rays will be evaluated for acetabular cup angle, acetabular cup migration, femoral stem position, femoral stem subsidence and femoral stem shift. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Muut tulostoimenpiteet
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Metal Ion / Cobalt
Aikaikkuna: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Metal Ion / Chromium
Aikaikkuna: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Metal Ion / Titanium
Aikaikkuna: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Renal Function / BUN
Aikaikkuna: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Renal Function / Creatinine
Aikaikkuna: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Renal Function / GFR
Aikaikkuna: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Tutkijat
Tutkijat
- Opintojohtaja: Hillary Overholser, Zimmer Biomet
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Ensisijainen valmistuminen
Opintojen valmistuminen (Todellinen)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvioitu)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Luun sairaudet
- Tuki- ja liikuntaelinten sairaudet
- Patologiset prosessit
- Nivelsairaudet
- Reumaattiset sairaudet
- Sidekudostaudit
- Autoimmuunisairaudet
- Immuunijärjestelmän sairaudet
- Nekroosi
- Patologiset tilat, merkit ja oireet
- Iho- ja sidekudostaudit
- Niveltulehdus
- Nivelrikko
- Niveltulehdus, nivelreuma
- Osteonekroosi
- Kirurgiset toimenpiteet, operatiivinen
- Nivelrintakehys, korvaava
- Nivelrikkolus
- Ortopediset toimenpiteet
- Plastiikkakirurgiatoimenpiteet
- Proteesin implantointi
- Nivelrintakehys, korvaava, lonkka
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- CMU2010-02H
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .